Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.
Department of Neurology, Rigshospitalet, Copenhagen, Denmark.
Acta Neurol Scand. 2020 Dec;142(6):637-640. doi: 10.1111/ane.13322. Epub 2020 Aug 5.
Subcutaneous immunoglobulin (SCIG) is effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Quality of life (QoL) increases following switch from intravenous administration to SCIG, but its correlation with clinical functioning is sparsely studied.
The aim of this study is to evaluate the correlation between QoL and clinical functioning in CIDP patients treated with SCIG.
Danish patients with CIDP with a disease duration <10 years and currently treated with SCIG were eligible for inclusion. QoL was assessed with EQ-5D-5L and disability by the Overall Disability Sum Score (ODSS) and Rasch-built Overall Disability Scale (RODS). Gait performance was evaluated by a 40-meter-walk test (40-MWT) and a 6-spot-step test (6-SST) along with assessment of muscle strength (Medical Research Council score [MRC]). Correlations between QoL and the measured scores were calculated.
Of 92 eligible patients, 44 were included. QoL on the visual analogue scale (VAS) was 65% (range: 15-90) of the level of healthy controls (P = .03) and correlated to impaired gait function by 40-MWT and 6-SST. QoL correlated to RODS and ODSS, whereas there was no correlation with the MRC score.
In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.
皮下免疫球蛋白（SCIG）是治疗慢性炎症性脱髓鞘性多发性神经病（CIDP）的有效方法。从静脉给药转换为 SCIG 治疗后，患者的生活质量（QoL）会提高，但 QoL 与临床功能的相关性研究较少。
本研究旨在评估接受 SCIG 治疗的 CIDP 患者的 QoL 与临床功能之间的相关性。
丹麦患有 CIDP 且病程<10 年且目前正在接受 SCIG 治疗的患者符合入选条件。使用 EQ-5D-5L 评估 QoL，使用总体残疾评分（ODSS）和基于 Rasch 的总体残疾量表（RODS）评估残疾程度。通过 40 米步行测试（40-MWT）和 6 点步测试（6-SST）评估步态表现，并评估肌肉力量（医学研究理事会评分[MRC]）。计算 QoL 与测量评分之间的相关性。
在 92 名符合条件的患者中，有 44 名患者入选。视觉模拟量表（VAS）上的 QoL 为健康对照组的 65%（范围：15-90）（P=0.03），与 40-MWT 和 6-SST 的步态功能受损相关。QoL 与 RODS 和 ODSS 相关，而与 MRC 评分无关。
在接受 SCIG 治疗的 CIDP 患者中，QoL 降低，与步态表现和残疾相关。
Zotero 插件